ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference31 articles.
1. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2. Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
3. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
4. Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
5. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Cited by 189 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. AutoCancer as an automated multimodal framework for early cancer detection;iScience;2024-07
2. Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine;Molecular Cancer;2024-03-09
3. Pathway-Based Analysis Using SVM-RFE for Gene Selection and Classification;Smart Innovation, Systems and Technologies;2024
4. Specific recognition of anFGFR2fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma;Journal for ImmunoTherapy of Cancer;2023-04
5. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma;Biomedicine & Pharmacotherapy;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3